Navigation Links
New technology capable of detection of 150 genetic syndromes from an amniocentesis
Date:4/5/2011

This release is available in Spanish.

Genetadi Biotech has presented to the scientific community meeting at the XXVI National Congress on Human Genetics held in Murcia - a prenatal diagnostic device based on amniocentesis. More concretely, it is based on microarray technology (genomic hybridisation genetic chips) and with a diagnostic resolution 100 times greater than the common cytogenetic techniques. The new device, known as Amniochip, is able to detect 150 genetic genetic syndromes. "This involves currently validated genetic syndromes, including malformations and idiopathic mental deficiency not detected with a conventional kariotype", explained Ms Silvia vila, co-director of Genetadi.

The scientists pointed out that one of the advantages of this innovative technique is the fact that "a cell culture is not necessary". Thus, "the waiting time for the results with the new device drops to 48 hours, in contrast to the three weeks it currently takes through conventional kariotype technique".

Nevertheless, from a clinical perspective, the procedure for the diagnosis does not vary, starting with a standard amniocentesis undertaken by the specialist gynaecologist. "The sample of amniotic liquid does not differ at all from the current amniocentesis procedure", explained doctor vila. "With the Amniochip only 8 or 10 ml of amniotic liquid are necessary in a tube, and which is sent to a laboratory via messenger, exactly as with the usual genetic trials".

The application of this new technology, through a prescription from the specialist in gynaecology and obstetrics, is especially suitable for all those pregnant women who require a conventional genetic study (kariotype or FISH). That is, those suspected from ecographs of having malformations, or with positive triple marker, or the over 35s. It is also suitable for couples with a history of miscarriage, or with a family history of genetic syndromes.

In those cases in which the research using this new technology found a result with doubtful clinical significance, "the DNA of the two progenitors were also analysed; in order to discard any family polymorphic alterations", explained Dr vila.

Scientific basis

The new device for enhanced prenatal diagnosis, developed by Genetadi "is based on Comparative Genomic Hybridisation" (aCGH) microarray technology. Using this technique, "the sample to study and a reference are marked with different fluorochromes. These DNA hybridise on a crystal which contains thousands of different segments of human DNA. The regions selected on the Amniochip belong to regions of the human genome involved in more than 150 already known syndromes. Subsequently, computer software is used to identify the areas of differential hybridisation between the patient and the DNA control, thus indicating the existence of an alteration in its dosage (microdeletion or microduplication)".


'/>"/>

Contact: Oihane Lakar
o.lakar@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. Scientists develop new technology for stroke rehabilitation
2. New device uses submarine technology to diagnose stroke quickly
3. New technology to improve early detection and prognosis of cancer
4. U of M researchers close in on technology for making renewable petroleum
5. University of Houston wins $1 million EPA grant to test diesel technology on buses
6. AMIA on meaningful use: Invest in people and technology
7. Cleveland Clinic researchers honored for contributions to science and technology
8. DHS Science and Technology Directorates science conference: Catastrophes and Complex Systems
9. NextCAT secures license agreement for advanced biofuel technology from Wayne State
10. New technology pinpoints genetic differences between cancer and non-cancer patients
11. Groundbreaking technology will revolutionize blood pressure measurement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... Portland, Oregon (PRWEB) , ... May 25, 2016 ... ... Base Set features a variety of fracture-specific plating options designed to address fractures ... provide industry-leading fracture fixation solutions. , The Acumed Ankle Plating System 3 is ...
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical Informatics Association ... the National Coordinator for Health IT (ONC) outlining a measurement approach to interoperability ... available when and where it was needed. The organization of health informatics professionals ...
(Date:5/25/2016)... SALT LAKE CITY, UTAH. (PRWEB) , ... May 25, 2016 , ... ... create efficiencies in healthcare information exchange, today announced that Charles W. Stellar has been ... served as WEDI’s interim CEO since January 2016. As an executive leader with more ...
(Date:5/25/2016)... Connecticut (PRWEB) , ... May 25, 2016 , ... ... the U.S. Food and Drug Administration (FDA) has granted the company’s orphan drug ... the company’s second orphan drug designation granted by the FDA. , Spinocerebellar ...
Breaking Biology Technology: